1h Free Analyst Time
The sickle cell disease treatment market is forecasted to grow by USD 3.34 billion during 2024-2029, accelerating at a CAGR of 16.2% during the forecast period. The report on the sickle cell disease treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high prevalence of sickle cell disease, government and nonprofit support, and improved healthcare infrastructure in emerging markets.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The sickle cell disease treatment market is segmented as below:
By Therapeutic Area
- Blood transfusion
- Pharmacotherapy
- Bone marrow transplant
By End-user
- Hospitals
- Specialty clinics
- Ambulatory surgical centers
By Indication
- Sickle cell anemia
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the sickle cell disease treatment market covers the following areas:
- Sickle Cell Disease Treatment Market sizing
- Sickle Cell Disease Treatment Market forecast
- Sickle Cell Disease Treatment Market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Therapeutic Area
9 Market Segmentation by End-user
10 Market Segmentation by Indication
11 Customer Landscape
12 Geographic Landscape
13 Drivers, Challenges, and Opportunity/Restraints
14 Competitive Landscape
15 Competitive Analysis
16 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global sickle cell disease treatment market: AbbVie Inc., Agios Inc., AstraZeneca Plc, bluebird bio Inc., Bristol Myers Squibb Co., CHIESI Farmaceutici SpA, CRISPR Therapeutics AG, Editas Medicine Inc., Emmaus Medical Inc., F. Hoffmann La Roche Ltd., Intellia Therapeutics Inc., Medunik USA, Novartis AG, Pfizer Inc., Prolong Pharmaceuticals LLC, Sanofi SA, and Vertex Pharmaceuticals Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is shift from symptom management to curative approaches."
According to the report, one of the major drivers for this market is the high prevalence of sickle cell disease.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Agios Inc.
- AstraZeneca Plc
- bluebird bio Inc.
- Bristol Myers Squibb Co.
- CHIESI Farmaceutici SpA
- CRISPR Therapeutics AG
- Editas Medicine Inc.
- Emmaus Medical Inc.
- F. Hoffmann La Roche Ltd.
- Intellia Therapeutics Inc.
- Medunik USA
- Novartis AG
- Pfizer Inc.
- Prolong Pharmaceuticals LLC
- Sanofi SA
- Vertex Pharmaceuticals Inc.
